国内第3波でのCOVID-19症例集積研究およびCOVID-19肺炎治療中の増悪時におけるバイオマーカー推移とマネジメントの検討（単施設研究）

期間内（2021 年 1 月）から変更になっており，早

期の抗ウイルス薬治療が開始されてきたことも結

果 に 影 響 し て い る 可 能 性 が あ る こ と，5．

COVID-19 に対するワクチン接種普及前の研究

であること，6．ステロイドの製剤や投与量調整

だけでなく，他の炎症抑制薬の効果や併用につい

ても更なる検討が必要になること，などである．

既 に RECOVERY（Randomised Evaluation of

1)

WHO Solidarity Trial Consortium, Pan H, Peto

R, Henao-Restrepo AM, Preziosi MP,

Sathiyamoorthy V, Abdool Karim Q, Alejandria

MM, Hernández García C, Kieny MP, Malekzadeh R, Murthy S, Reddy KS, Roses Periago M,

Abi Hanna P, Ader F, Al-Bader AM, Alhasawi

A, Allum E, Alotaibi A, Alvarez-Moreno CA,

Appadoo S, Asiri A, Aukrust P, Barratt-Due A,

206

謙一郎

Bellani S, Branca M, Cappel-Porter HBC,

Cerrato N, Chow TS, Como N, Eustace J, García

PJ, Godbole S, Gotuzzo E, Griskevicius L, Hamra

R, Hassan M, Hassany M, Hutton D, Irmansyah

I, Jancoriene L, Kirwan J, Kumar S, Lennon P,

Lopardo G, Lydon P, Magrini N, Maguire T,

Manevska S, Manuel O, McGinty S, Medina MT,

Mesa Rubio ML, Miranda-Montoya MC, Nel J,

Nunes EP, Perola M, Portolés A, Rasmin MR,

Raza A, Rees H, Reges PPS, Rogers CA, Salami

K, Salvadori MI, Sinani N, Sterne JAC, Stevanovikj M, Tacconelli E, Tikkinen KAO, Trelle S,

Zaid H, Røttingen JA and Swaminathan S :

Repurposed Antiviral Drugs for Covid-19 Interim WHO Solidarity Trial Results. N Engl J

Med. 384 : 497-511, 2021.

2) Beigel JH, Tomashek KM, Dodd LE, Mehta AK,

Zingman BS, Kalil AC, Hohmann E, Chu HY,

Luetkemeyer A, Kline S, Lopez de Castilla D,

Finberg RW, Dierberg K, Tapson V, Hsieh L,

Patterson TF, Paredes R, Sweeney DA, Short

WR, Touloumi G, Lye DC, Ohmagari N, Oh MD,

Ruiz-Palacios GM, Benfield T, Fätkenheuer G,

Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess

TH, Bonnett T, Green M, Makowski M, Osinusi

A, Nayak S and Lane HC for ACTT-1 Study

Group Members : Remdesivir for the Treatment

of Covid-19-Final Report. N Engl J Med. 383 :

1813-1826, 2020.

3) RECOVERY Collaborative Group, Horby P, Lim

WS, Emberson JR, Mafham M, Bell JL, Linsell L,

Staplin N, Brightling C, Ustianowski A, Elmahi

E, Prudon B, Green C, Felton T, Chadwick D,

Rege K, Fegan C, Chappell LC, Faust SN, Jaki T,

Jeffery K, Montgomery A, Rowan K, Juszczak

E, Baillie JK, Haynes R and Landray MJ :

Dexamethasone in Hospitalized Patients with

Covid-19. N Engl J Med. 384 : 693-704, 2021.

4) Kalil AC, Patterson TF, Mehta AK, Tomashek

KM, Wolfe CR, Ghazaryan V, Marconi VC,

Ruiz-Palacios GM, Hsieh L, Kline S, Tapson V,

Iovine NM, Jain MK, Sweeney DA, El Sahly HM,

Branche AR, Regalado Pineda J, Lye DC,

Sandkovsky U, Luetkemeyer AF, Cohen SH,

Finberg RW, Jackson PEH, Taiwo B, Paules CI,

Arguinchona H, Erdmann N, Ahuja N, Frank M,

Oh MD, Kim ES, Tan SY, Mularski RA, Nielsen

H, Ponce PO, Taylor BS, Larson L, Rouphael NG,

Saklawi Y, Cantos VD, Ko ER, Engemann JJ,

Amin AN, Watanabe M, Billings J, Elie MC,

Davey RT, Burgess TH, Ferreira J, Green M,

Makowski M, Cardoso A, de Bono S, Bonnett T,

ほか９名

5)

6)

7)

8)

9)

10)

11)

Proschan M, Deye GA, Dempsey W, Nayak SU,

Dodd LE and Beigel JH for ACTT-2 Study

Group Members : Baricitinib plus Remdesivir

for Hospitalized Adults with Covid-19. N Engl J

Med. 384 : 795-807, 2021.

Moonla C, Sosothikul D, Chiasakul T, Rojnuckarin P and Uaprasert N : Anticoagulation and

In-Hospital Mortality From Coronavirus Disease 2019 : A Systematic Review and MetaAnalysis. Clin Appl Thromb Hemost. 27 :

10760296211008999, 2021.

Westblade LF, Simon MS and Satlin MJ :

Bacterial coinfections in coronavirus disease

2019. Trends Microbiol. S0966-842X(21)000949, 2021.

診療の手引き検討委員会．新型コロナウイルス

感染症（COVID-19）診療の手引き第 5.1 版，

2021．

Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng VC, Edwards KM, Gandhi

R, Gallagher J, Muller WJ, O'Horo JC, Shoham S,

Murad MH, Mustafa RA, Sultan S and Falck-Ytter Y : Infectious Diseases Society of America

Guidelines on the Treatment and Management

of Patients with COVID-19. Version 4.4.1.

〈https://www.idsociety.org/practice-guideline/

covid-19-guideline-treatment-and-manageme

nt/〉（2021/07/29 アクセス）

COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment

Guidelines. National Institutes of Health.

〈https://www.covid19treatmentguidelines.nih.

gov/〉

（2021/07/29 アクセス）

RECOVERY Collaborative Group : Tocilizumab

in patients admitted to hospital with COVID-19

(RECOVERY) : a randomised, controlled, openlabel, platform trial. Lancet. 397 : 1637- 1645,

2021.

REMAP-CAP Investigators, Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD,

Arabi YM, Annane D, Beane A, van Bentum-Puijk W, Berry LR, Bhimani Z, Bonten

MJM, Bradbury CA, Brunkhorst FM, Buzgau A,

Cheng AC, Detry MA, Duffy EJ, Estcourt LJ,

Fitzgerald M, Goossens H, Haniffa R, Higgins

AM, Hills TE, Horvat CM, Lamontagne F,

Lawler PR, Leavis HL, Linstrum KM, Litton E,

Lorenzi E, Marshall JC, Mayr FB, McAuley DF,

McGlothlin A, McGuinness SP, McVerry BJ,

Montgomery SK, Morpeth SC, Murthy S, Orr K,

Parke RL, Parker JC, Patanwala AE, Pettilä V,

Rademaker E, Santos MS, Saunders CT,

Seymour CW, Shankar-Hari M, Sligl WI,

COVID-19 症例集積と増悪時の対応

12)

13)

14)

15)

16)

17)

18)

Turgeon AF, Turner AM, van de Veerdonk FL,

Zarychanski R, Green C, Lewis RJ, Angus DC,

McArthur CJ, Berry S, Webb SA and Derde

LPG : Interleukin-6 Receptor Antagonists in

Critically Ill Patients with Covid-19. N Engl J

Med. 384 : 1491-1502, 2021.

Yaita K, Takeuchi H, Miura H, Yonemura S, Isa

K, Kawasaki W, Yamanaka M, Nadayoshi S and

Yamamoto S : Case Series of Elderly COVID-19

patients treated in a Single Center : The Importance of Managing Cases Considered Mild-toModerate. Journal of Hospital General Medicine.

3 : 99-103, 2021.

Sato R, Ishikane M, Kinoshita N, Suzuki T,

Nakamoto T, Hayakawa K, Bekki N, Hara H and

Ohmagari N : A new challenge of unfractionated

heparin anticoagulation treatment for moderate

to severe COVID-19 in Japan. Glob Health Med.

2 : 190-192, 2020.

Matsunaga N, Hayakawa K, Terada M, Ohtsu H,

Asai Y, Tsuzuki S, Suzuki S, Toyoda A, Suzuki

K, Endo M, Fujii N, Suzuki M, Saito S, Uemura Y,

Shibata T, Kondo M, Izumi K, Terada-Hirashima J, Mikami A, Sugiura W and Ohmagari N :

Clinical epidemiology of hospitalized patients

with COVID-19 in Japan : Report of the

COVID-19 REGISTRY JAPAN. Clin Infect Dis.

ciaa1470, 2020. [Online ahead of print]

Levi M, Thachil J, Iba T and Levy JH :

Coagulation abnormalities and thrombosis in

patients with COVID-19. Lancet Haematol. 7 :

e438-e440, 2020.

Han Y, Zhang H, Mu S, Wei W, Jin C, Tong C,

Song Z, Zha Y, Xue Y and Gu G : Lactate dehydrogenase, an independent risk factor of severe

COVID-19 patients : a retrospective and observational study. Aging (Albany NY). 12 : 1124511258, 2020.

南順也，斧沢京子，小野雄一，柳田雄一郎，下野

信行．少量ステロイド投与により挿管回避可能

であった COVID-19 の 6 症例．日本感染症学

会．

〈https://www.kansensho.or.jp/uploads/files/to

pics/2019ncov/covid19_casereport_200512_12.

pdf〉

（2020．5．12 公開）

Ranjbar K, Moghadami M, Mirahmadizadeh A,

Fallahi MJ, Khaloo V, Shahriarirad R, Erfani A,

Khodamoradi Z and Gholampoor Saadi MH :

Methylprednisolone or dexamethasone, which

one is superior corticosteroid in the treatment of

hospitalized COVID-19 patients : a triple-blinded randomized controlled trial. BMC Infect

Dis. 21 : 337, 2021.

19)

20)

21)

22)

23)

24)

25)

26)

207

Edalatifard M, Akhtari M, Salehi M, Naderi Z,

Jamshidi A, Mostafaei S, Najafizadeh SR,

Farhadi E, Jalili N, Esfahani M, Rahimi B,

Kazemzadeh H, Mahmoodi Aliabadi M, Ghazanfari T, Sattarian M, Ebrahimi Louyeh H,

Raeeskarami SR, Jamalimoghadamsiahkali S,

Khajavirad N, Mahmoudi M and Rostamian A :

Intravenous methylprednisolone pulse as a

treatment for hospitalised severe COVID-19

patients : results from a randomised controlled

clinical trial. Eur Respir J. 56 : 2002808, 2020.

Pinzón MA, Ortiz S, Holguín H, Betancur JF,

Cardona Arango D, Laniado H, Arias Arias C,

Muñoz B, Quiceno J, Jaramillo D and Ramirez Z :

Dexamethasone vs methylprednisolone high

dose for Covid-19 pneumonia. PLoS One. 16 :

e0252057, 2021.

Tuberculosis Surveillance Center. Tuberculosis

in Japan ‒ annual report 2020. Department of

Epidemiology and Clinical Research, the Research Institute of Tuberculosis : Tokyo, Japan.

2020.

田中純子，内田茂治，山崎一美，池田健次，相崎

英樹，日野啓輔，江口有一郎，三浦宜彦，宮坂昭

生，島上哲朗，片山惠子．厚生労働科学研究費

補助金（肝炎等克服政策研究事業）

「急性感染も

含めた肝炎ウイルス感染状況・長期経過と治療

導入対策に関する研究」平成 27 年度総括研究

報告書

〈https : //mhlw-grants.niph.go.jp/project/25543

/1〉(2021/07/29 アクセス)

Campbell C, Andersson M, Ansari MA, Moswela O, Misbah SA, Klenerman P and Matthews

PC : Risk of reactivation of hepatitis B virus

(HBV) and tuberculosis (TB) and complications

of hepatitis C virus (HCV) following Tocilizumab

therapy : A systematic review to inform risk

assessment in the COVID era. medRxiv. 2021.

03. 22. 21254128, 2021.（2021/08/02 アクセス）

中外製薬．アクテムラ®点滴静注用 80 mg・200

mg・400 mg 添付文書 2020 年 4 月改訂（第 1

版）．

日本イーライリリー．オルミエント®錠 4 mg・

2 mg 添付文書 2021 年 4 月改訂（第 4 版，効能

変更）

RECOVERY (Randomised Evaluation of

COVID-19 Therapy)

〈https://www.recoverytrial.net/〉(2021/07/30

アクセス)

(Received for publication August 19, 2021)

...